Clinical trial NCT02289300: A Study to Evaluate a Study Drug, DCB-BO1202, for Alleviating Liver Fibrosis in Liver Cancer Patients
Official title: A Phase II Randomized, Double-Blind, Placebo Controlled, Parallel Study of DCB-BO1202 for Alleviating Liver Fibrosis in HBV Patients With Intermediate Hepatocellular Carcinoma Receiving Loco-regional Therapies
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Liver Fibrosis
HEPATITIS B CHRONIC
Hepatocellular Carcinoma
Lead sponsor: A2 Healthcare Taiwan Corporation
Sponsor class: INDUSTRY
Collaborators: name: GoldenMed BioTechnology
First posted: 2014-11-13
Enrollment: 0
Sex: ALL
Minimum age (years): 20
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether an investigational drug DCB-BO1202 is effective and safe in the treatment of liver fibrosis in HBV patients having experienced intermediate stage hepatocellular carcinoma (HCC)

Detailed description: The study will include the first 188 subjects who are randomized. The purpose of study is to collect efficacy results to evaluate treatment effect on the primary endpoint. The second endpoints is to evaluate drug safety on the incidence of the primary endpoint through the treatment period.

Eligibility criteria: Inclusion Criteria:

1. Aged 20-65 years (inclusive) of either gender
2. With evidence of HBV infection confirmed by positive for Hepatitis B virus antigen (HBsAg)
3. With Barcelona Clinic Liver Cancer (BCLC) intermediate stage (BCLC-B) hepatocellular carcinoma (HCC)
4. Having received radiofrequency ablation (RFA) or transarterial embolization (TAE) for hepatitis B virus (HBV) related hepatocellular carcinoma at least 4 weeks before Screening
5. With liver stiffness measurement (assessed by Fibroscan®) of 7-20 kPa
6. Able to understand and willing to sign the informed consent

Exclusion Criteria:

1. Evidence or history of chronic hepatitis caused by Hepatitis C virus (HCV)
2. With abnormal organ functions such as absolute neutrophil count (ANC) \< 1500 /μL, hemoglobin \< 9 gm/dL, platelets \< 50,000 /μL, creatinine \> 2 mg/dL, alanine aminotransferase (AST) or ALT \> 5 X upper normal limit of the current institution; bilirubin \> 2.5 mg/dL, prothrombin time (PT) prolongation \> 4 sec above upper limit of normal
3. With uncontrolled infection or serious infection within the past 4 weeks
4. With any other carcinoma except skin cancer
5. Women who are pregnant or breast-feeding or with child-bearing potential but unable or unwilling to practice a highly effective means of contraception
6. Active substance abuse, including alcohol, which, in the opinion of the investigator, risks impairing the ability of the patient to comply with the protocol
7. History of allergy to any substance of investigational products
8. With known human immunodeficiency virus (HIV) infection
9. Judged to be not applicable to this study by investigator such as difficulty of follow-up observation
10. With any other serious diseases/medical history considered by the investigator not in the condition to enter the trial
11. Administered with any anti-HBV drugs within 4 weeks of entering this study. (Note: Anti-HBV treatments are allowed to be taken during study period when necessary.)
12. Having participated other investigational study within 4 weeks of entering this study

Primary outcomes:
measure: Change from baseline in liver stiffness measurement (kPa) assessed by Fibroscan® at Final visit
timeFrame: 96 weeks
Secondary outcomes:
measure: Change from baseline in liver stiffness measurement (kPa) assessed by (Fibroscan®) at each post-treatment visit
timeFrame: Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84
measure: Changes from baseline in biomarkers associated with liver fibrosis at each post-treatment visit compared to baseline
timeFrame: Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96
measure: Changes from baseline in hepatic functions such as liver enzymes, albumin, direct bilirubin and international normalize ratio (INR) at each post-treatment visit compared to baseline
timeFrame: Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96
measure: Change from baseline in log10 HBV deoxyribonucleic acid (DNA) measured by Polymerase chain reaction (PCR) assay at each post-treatment visit and each of post-study follow-up visits compared to baseline
timeFrame: Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96
measure: Transition of HBV DNA detectable status (e.g. <500 copies/mL) by PCR at each post-treatment visit from baseline
timeFrame: Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96
measure: Change in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue total score and sub-scores compared to baseline at each post-treatment visit
timeFrame: Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96
measure: Overall survival rates at Week-48 and Week-96 visits
timeFrame: Weeks 48, 96
measure: Recurrence rate at Week-96 visit
timeFrame: Week 96
measure: Time to recurrence of cancer
timeFrame: Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96
measure: Incidence of adverse events (AEs)
timeFrame: Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96
measure: Changes from baseline to post-treatment visits in vital signs, laboratory examination, and physical examinations results
timeFrame: Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
affiliation: Hepatitis Research Center, Department of Surgery, National Taiwan University Hospital
name: Kai-Wen Huang, MD
role: PRINCIPAL_INVESTIGATOR
References: